Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

When the FRAX(®) test is applied to controlled clinical trials.

Fiore CE, Gaudio A.

Clin Cases Miner Bone Metab. 2012 Sep;9(3):135-7. Epub 2012 Dec 20.

PMID:
23289024
[PubMed]
Free PMC Article
2.

Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.

Siris ES, Baim S, Nattiv A.

Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Review.

PMID:
20107292
[PubMed - indexed for MEDLINE]
3.

The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.

Stevenson M, Davis S, Lloyd-Jones M, Beverley C.

Health Technol Assess. 2007 Feb;11(4):1-134. Review.

PMID:
17280622
[PubMed - indexed for MEDLINE]
Free Article
4.

[Usefulness of FRAX and future issues in women's health].

Hashimoto K, Ishitani K, Ohta H.

Clin Calcium. 2009 Dec;19(12):1742-8. doi: CliCa091217421744. Review. Japanese.

PMID:
19949265
[PubMed - indexed for MEDLINE]
5.

[Application of FRAX for health check-ups].

Fujiwara S.

Clin Calcium. 2009 Dec;19(12):1730-4. doi: CliCa091217301734. Review. Japanese.

PMID:
19949263
[PubMed - indexed for MEDLINE]
6.

[Evaluation of fracture risk in osteoporosis].

Szathmári M.

Orv Hetil. 2011 Aug 14;152(33):1304-11. doi: 10.1556/OH.2011.29191. Review. Hungarian.

PMID:
21824857
[PubMed - indexed for MEDLINE]
Free Article
7.

Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M; FRAX(®) Position Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):240-62. doi: 10.1016/j.jocd.2011.05.015.

PMID:
21810532
[PubMed - indexed for MEDLINE]
8.

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.

Health Technol Assess. 2005 Jun;9(22):1-160. Review.

PMID:
15929857
[PubMed - indexed for MEDLINE]
Free Article
9.

FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Cauley JA, El-Hajj Fuleihan G, Luckey MM; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):237-9. doi: 10.1016/j.jocd.2011.05.016.

PMID:
21810531
[PubMed - indexed for MEDLINE]
10.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

PMID:
21175240
[PubMed - indexed for MEDLINE]
11.

[Daily practice using guidelines for prevention and treatment of osteoporosis. Risk factors for fracture and guideline for prevention of fracture].

Fujiwara S.

Clin Calcium. 2008 Aug;18(8):1079-83. doi: CliCa080810791083. Review. Japanese.

PMID:
18677043
[PubMed - indexed for MEDLINE]
12.

[Daily practice using the guidelines for prevention and treatment of osteoporosis. Use of clinical risk factors for osteoporotic fractures in the evaluation of risk of future fracture].

Gorai I.

Clin Calcium. 2008 Aug;18(8):1135-40. doi: CliCa080811351140. Review. Japanese.

PMID:
18677051
[PubMed - indexed for MEDLINE]
13.

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M.

Health Technol Assess. 2007 Mar;11(7):iii-iv, ix-xi, 1-231. Review.

PMID:
17311734
[PubMed - indexed for MEDLINE]
Free Article
14.

Critical points in strategies for the diagnosis and treatment of osteoporosis.

Lorenc RS, Misiorowski W, Karczmarewicz E.

Endokrynol Pol. 2009 Mar-Apr;60(2):124-33. Review.

PMID:
19396756
[PubMed - indexed for MEDLINE]
15.

Official Positions for FRAX® clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Broy SB, Tanner SB; FRAX(®)Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):184-9. doi: 10.1016/j.jocd.2011.05.012.

PMID:
21810523
[PubMed - indexed for MEDLINE]
16.

Assessment of fracture risk.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Eur J Radiol. 2009 Sep;71(3):392-7. doi: 10.1016/j.ejrad.2008.04.061. Epub 2009 Aug 28. Review.

PMID:
19716672
[PubMed - indexed for MEDLINE]
17.

Official Positions for FRAX® clinical regarding prior fractures from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Blank RD; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):205-11. doi: 10.1016/j.jocd.2011.05.009.

PMID:
21810526
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk